Cargando…

Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline

Aim: We investigated whether retinal arteriolosclerosis (RA) could be used for cardiovascular disease (CVD) risk stratification of individuals categorized according to the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Blood Pressure (BP) guideline. Methods: We studied 29...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Satoshi, Kaneko, Hidehiro, Kamon, Tatsuya, Suzuki, Yuta, Yano, Yuichiro, Okada, Akira, Itoh, Hidetaka, Morita, Kojiro, Fukui, Akira, Fujiu, Katsuhito, Michihata, Nobuaki, Jo, Taisuke, Takeda, Norifumi, Morita, Hiroyuki, Nakamura, Sunao, Yokoo, Takashi, Nishiyama, Akira, Node, Koichi, Yasunaga, Hideo, Komuro, Issei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529405/
https://www.ncbi.nlm.nih.gov/pubmed/34866070
http://dx.doi.org/10.5551/jat.63262
_version_ 1784801485520896000
author Matsuoka, Satoshi
Kaneko, Hidehiro
Kamon, Tatsuya
Suzuki, Yuta
Yano, Yuichiro
Okada, Akira
Itoh, Hidetaka
Morita, Kojiro
Fukui, Akira
Fujiu, Katsuhito
Michihata, Nobuaki
Jo, Taisuke
Takeda, Norifumi
Morita, Hiroyuki
Nakamura, Sunao
Yokoo, Takashi
Nishiyama, Akira
Node, Koichi
Yasunaga, Hideo
Komuro, Issei
author_facet Matsuoka, Satoshi
Kaneko, Hidehiro
Kamon, Tatsuya
Suzuki, Yuta
Yano, Yuichiro
Okada, Akira
Itoh, Hidetaka
Morita, Kojiro
Fukui, Akira
Fujiu, Katsuhito
Michihata, Nobuaki
Jo, Taisuke
Takeda, Norifumi
Morita, Hiroyuki
Nakamura, Sunao
Yokoo, Takashi
Nishiyama, Akira
Node, Koichi
Yasunaga, Hideo
Komuro, Issei
author_sort Matsuoka, Satoshi
collection PubMed
description Aim: We investigated whether retinal arteriolosclerosis (RA) could be used for cardiovascular disease (CVD) risk stratification of individuals categorized according to the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Blood Pressure (BP) guideline. Methods: We studied 291,522 participants without a history of CVD and not taking any BP-lowering medications from the JMDC Claims Database. RA was defined as Keith–Wagener–Barker system grade ≥ 1. Each participant was classified into one of the six groups: (1) normal or elevated BP without RA, (2) normal or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA. Results: Median (interquartile range) age was 46 (40–53) years, and 141,397 (48.5%) of the participants were men. During a mean follow-up of 1,223±830 days, 527 myocardial infarction (MI), 5,718 angina pectoris, 2,890 stroke, and 5,375 heart failure (HF) events occurred. Multivariable Cox regression analyses revealed that the risk of CVD increased with BP category, and this association was pronounced by the presence of RA. Compared with normal or elevated BP without RA, the hazard ratios (HRs) for MI (HR 1.17, 95% CI 0.93–1.47) were higher in stage 1 hypertension without RA. The HRs for MI further increased in stage 1 hypertension with RA (1.86 [1.17–2.95]). This association was present in stroke and HF. Conclusion: Incorporation of the assessment for RA may facilitate the CVD risk stratification of people classified based on the 2017 ACC/AHA BP guideline, particularly for those categorized in stage 1 hypertension.
format Online
Article
Text
id pubmed-9529405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-95294052022-10-18 Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline Matsuoka, Satoshi Kaneko, Hidehiro Kamon, Tatsuya Suzuki, Yuta Yano, Yuichiro Okada, Akira Itoh, Hidetaka Morita, Kojiro Fukui, Akira Fujiu, Katsuhito Michihata, Nobuaki Jo, Taisuke Takeda, Norifumi Morita, Hiroyuki Nakamura, Sunao Yokoo, Takashi Nishiyama, Akira Node, Koichi Yasunaga, Hideo Komuro, Issei J Atheroscler Thromb Original Article Aim: We investigated whether retinal arteriolosclerosis (RA) could be used for cardiovascular disease (CVD) risk stratification of individuals categorized according to the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Blood Pressure (BP) guideline. Methods: We studied 291,522 participants without a history of CVD and not taking any BP-lowering medications from the JMDC Claims Database. RA was defined as Keith–Wagener–Barker system grade ≥ 1. Each participant was classified into one of the six groups: (1) normal or elevated BP without RA, (2) normal or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA. Results: Median (interquartile range) age was 46 (40–53) years, and 141,397 (48.5%) of the participants were men. During a mean follow-up of 1,223±830 days, 527 myocardial infarction (MI), 5,718 angina pectoris, 2,890 stroke, and 5,375 heart failure (HF) events occurred. Multivariable Cox regression analyses revealed that the risk of CVD increased with BP category, and this association was pronounced by the presence of RA. Compared with normal or elevated BP without RA, the hazard ratios (HRs) for MI (HR 1.17, 95% CI 0.93–1.47) were higher in stage 1 hypertension without RA. The HRs for MI further increased in stage 1 hypertension with RA (1.86 [1.17–2.95]). This association was present in stroke and HF. Conclusion: Incorporation of the assessment for RA may facilitate the CVD risk stratification of people classified based on the 2017 ACC/AHA BP guideline, particularly for those categorized in stage 1 hypertension. Japan Atherosclerosis Society 2022-10-01 2021-12-04 /pmc/articles/PMC9529405/ /pubmed/34866070 http://dx.doi.org/10.5551/jat.63262 Text en 2022 Japan Atherosclerosis Society https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Original Article
Matsuoka, Satoshi
Kaneko, Hidehiro
Kamon, Tatsuya
Suzuki, Yuta
Yano, Yuichiro
Okada, Akira
Itoh, Hidetaka
Morita, Kojiro
Fukui, Akira
Fujiu, Katsuhito
Michihata, Nobuaki
Jo, Taisuke
Takeda, Norifumi
Morita, Hiroyuki
Nakamura, Sunao
Yokoo, Takashi
Nishiyama, Akira
Node, Koichi
Yasunaga, Hideo
Komuro, Issei
Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
title Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
title_full Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
title_fullStr Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
title_full_unstemmed Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
title_short Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
title_sort incorporation of retinal arteriolosclerosis into risk stratification of blood pressure category according to the 2017 acc/aha blood pressure guideline
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529405/
https://www.ncbi.nlm.nih.gov/pubmed/34866070
http://dx.doi.org/10.5551/jat.63262
work_keys_str_mv AT matsuokasatoshi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT kanekohidehiro incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT kamontatsuya incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT suzukiyuta incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT yanoyuichiro incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT okadaakira incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT itohhidetaka incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT moritakojiro incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT fukuiakira incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT fujiukatsuhito incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT michihatanobuaki incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT jotaisuke incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT takedanorifumi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT moritahiroyuki incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT nakamurasunao incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT yokootakashi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT nishiyamaakira incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT nodekoichi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT yasunagahideo incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline
AT komuroissei incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline